BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization

Monday, December 8, 2008 General News J E 4
PRINCETON, N.J., Dec. 8 BioWa, Inc., announced today thatit licensed to GlaxoSmithKline (NYSE: GSK) its POTELLIGENT(R) Technology foruse in developing and commercializing select GSK antibodies with enhancementof antibody-dependent cellular cytotoxicity (ADCC).

"GSK is recognized as a key player in the field of antibody drugdiscovery," said Dr. Masamichi Koike, BioWa President and CEO. "We believethis represents an important opportunity to promote the development of moreeffective targeted treatments for debilitating diseases where enhanced ADCCmight offer a significant therapeutic benefit."

Under the terms of the agreement, BioWa will provide GSK with non-exclusive commercial rights to use the technology for multiple antibodies. Inreturn, BioWa will receive technology access fees, and may receive milestonepayments and royalties from resulting products which are developed by GSK.Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibodytherapeutics, by enhancing ADCC, one of the major mechanisms of action forantibody therapeutics. POTELLIGENT(R) Technology involves the reduction of theamount of fucose in the carbohydrate structure of an antibody using aproprietary fucosyltransferase-knockout CHO cell line as a production cell.Research shows that POTELLIGENT(R) Technology dramatically enhances ADCCactivity of an antibody in vitro, and significantly increases potency andefficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies arebeing investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan'sleading pharmaceutical and largest biotech company, and is the exclusiveworldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platformconsists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating asuperior antibody molecule with enhanced ADCC and CDC activities. BioWa isoffering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under alicense to maximize the value of these technologies. Together with Kyowa HakkoKirin, BioWa is focused on development of ADCC/CDC enhanced monoclonalantibody-based therapeutics to fight cancer and other life-threatening anddebilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks ofKyowa Hakko Kirin Co., Ltd. All rights are reserved.

SOURCE BioWa, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
ATS Medical Provides Update on US Commercializatio...
Start 2009 with The Chopra Center's Signature Self...